KILITCH

Kilitch Drugs(I) Share Price

₹418.75 -7.65 (-1.79%)

25 Jun, 2025 01:30

SIP TrendupStart SIP in KILITCH

Start SIP

Performance

  • Low
  • ₹413
  • High
  • ₹435
  • 52 Week Low
  • ₹300
  • 52 Week High
  • ₹499
  • Open Price₹435
  • Previous Close₹426
  • Volume8,920

Investment Returns

  • Over 1 Month -9.42%
  • Over 3 Month + 17.56%
  • Over 6 Month + 28.99%
  • Over 1 Year + 28.87%
SIP Lightning

Smart Investing Starts Here Start SIP with Kilitch Drugs(I) for Steady Growth!

Invest Now

Kilitch Drugs(I) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.6
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 673
  • P/B Ratio
  • 3.6
  • Average True Range
  • 21.25
  • EPS
  • 16.6
  • Dividend Yield
  • 0
  • MACD Signal
  • 8.97
  • RSI
  • 41.33
  • MFI
  • 72.78

Kilitch Drugs(I) Financials

Kilitch Drugs(I) Technicals

EMA & SMA

Current Price
₹418.75
-7.65 (-1.79%)
pointer
  • stock-down_img
  • Bearish Moving Average 9
  • stock-up_img
  • Bullish Moving Average 7
  • 20 Day
  • ₹438.81
  • 50 Day
  • ₹417.58
  • 100 Day
  • ₹389.54
  • 200 Day
  • ₹365.34

Resistance and Support

422.25 Pivot Speed
  • R3 453.50
  • R2 444.25
  • R1 431.50
  • S1 409.50
  • S2 400.25
  • S3 387.50

What's your outlook on Kilitch Drugs(I)?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Kilitch Drugs India has an operating revenue of Rs. 198.32 Cr. on a trailing 12-month basis. An annual revenue growth of 32% is outstanding, Pre-tax margin of 17% is great, ROE of 13% is good. The company has a reasonable debt to equity of 14%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 21% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 66 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Kilitch Drugs(I) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-19 Audited Results
2025-02-11 Quarterly Results
2024-11-12 Quarterly Results
2024-08-08 Quarterly Results
2024-05-27 Quarterly Results

Kilitch Drugs(I) F&O

Kilitch Drugs(I) Shareholding Pattern

69.23%
0%
0%
25.57%
5.2%

About Kilitch Drugs(I)

  • NSE Symbol
  • KILITCH
  • BSE Symbol
  • 524500
  • Managing Director
  • Mr. Mukund P Mehta
  • ISIN
  • INE729D01010

Similar Stocks to Kilitch Drugs(I)

Kilitch Drugs(I) FAQs

Kilitch Drugs(I) share price is ₹418 As on 25 June, 2025 | 01:16

The Market Cap of Kilitch Drugs(I) is ₹673.4 Cr As on 25 June, 2025 | 01:16

The P/E ratio of Kilitch Drugs(I) is 25.6 As on 25 June, 2025 | 01:16

The PB ratio of Kilitch Drugs(I) is 3.6 As on 25 June, 2025 | 01:16

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23